

# Isabella Sperduti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/55219/publications.pdf>

Version: 2024-02-01

387  
papers

10,367  
citations

47409

49  
h-index

71088

80  
g-index

396  
all docs

396  
docs citations

396  
times ranked

19169  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet-rich plasma for genital lichen sclerosus: analysis and results of 94 patients. Are there gender-related differences in symptoms and therapeutic response to PRP?. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1558-1562.	1.1	9
2	HIPK2 Cooperates with KRAS Signaling and Associates with Colorectal Cancer Progression. <i>Molecular Cancer Research</i> , 2022, 20, 686-698.	1.5	5
3	First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 439-439.	0.8	2
4	CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CLO22-084.	2.3	0
5	Prognostic Role of the Removed Vaginal Cuff and Its Correlation with L1CAM in Low-Risk Endometrial Adenocarcinoma. <i>Cancers</i> , 2022, 14, 34.	1.7	2
6	The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis. <i>Anticancer Research</i> , 2022, 42, 211-216.	0.5	7
7	Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections. <i>Microbiology Spectrum</i> , 2022, 10, e0035122.	1.2	19
8	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
9	Oncological Outcomes of Robotic Lobectomy and Radical Lymphadenectomy for Early-Stage Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2173.	1.0	12
10	Lymphadenectomy for lung carcinoids: Which factors may predict nodal upstaging? A multi centric, retrospective study. <i>Journal of Surgical Oncology</i> , 2022, , .	0.8	2
11	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCC) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	0.9	6
12	External Validation of a Prognostic Score for Survival in Lung Carcinoids. <i>Cancers</i> , 2022, 14, 2601.	1.7	1
13	T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
14	Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy. <i>World Journal of Urology</i> , 2021, 39, 1869-1877.	1.2	27
15	Safety and Feasibility of Outpatient Surgery in Benign Prostatic Hyperplasia: a Systematic Review and Meta-Analysis. <i>Journal of Endourology</i> , 2021, 35, 395-408.	1.1	20
16	Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience. <i>European Journal of Surgical Oncology</i> , 2021, 47, 143-148.	0.5	8
17	Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience. <i>Cancers</i> , 2021, 13, 523.	1.7	6
18	Pancreatic ductal adenocarcinoma and distal cholangiocarcinoma: a proposal of preoperative diagnostic score for differential diagnosis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 10.	0.8	3

#	ARTICLE	IF	CITATIONS
19	A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma. <i>In Vivo</i> , 2021, 35, 507-515.	0.6	5
20	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	1.1	5
21	Real-time ultrasound virtual navigation in <sc>3D PET</sc>/<sc>CT</sc> volumes for superficial lymph node evaluation: innovative fusion examination. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 766-772.	0.9	11
22	Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3073-3080.	1.2	20
23	Survival Analysis in Single N2 Station Lung Adenocarcinoma: The Prognostic Role of Involved Lymph Nodes and Adjuvant Therapy. <i>Cancers</i> , 2021, 13, 1326.	1.7	4
24	Which Is the Best Treatment in Recurrent Thymoma? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1559.	1.7	3
25	Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12516-e12516.	0.8	0
26	Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience. <i>Anticancer Research</i> , 2021, 41, 2553-2561.	0.5	2
27	TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13010-e13010.	0.8	0
28	Hemorrhagic Attitude in Frameless and Frame-Based Stereotactic Biopsy for Deep-Seated Primary Central Nervous System Lymphomas in Immunocompetent Patients: A Multicentric Analysis of the Last Twenty Years. <i>World Neurosurgery</i> , 2021, 149, e1017-e1025.	0.7	4
29	Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. <i>Cell Death and Disease</i> , 2021, 12, 636.	2.7	20
30	Thyroid dysfunction in COVID-19 patients. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2735-2739.	1.8	39
31	Serological response to COVID-19 vaccination in patients with cancer older than 80 years. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1253-1255.	0.5	33
32	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients'™ data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	3.4	14
33	The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1936-1945.	0.5	2
34	Surgical treatment of solitary intradural extramedullary spinal cord metastases from solid cancers of non-neurogenic origin. A multicenter study. <i>Journal of Neuro-Oncology</i> , 2021, 154, 101-112.	1.4	3
35	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
36	Nodal Upstaging Evaluation After Robotic-Assisted Lobectomy for Early-Stage Non-small Cell Lung Cancer Compared to Video-Assisted Thoracic Surgery and Thoracotomy: A Retrospective Single Center Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 666158.	0.6	19

#	ARTICLE	IF	CITATIONS
37	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 351-360.	1.1	7
38	Validation of a prognostic model including the number of harvested lymph-nodes in the setting of non-small cell lung cancer patients undergoing curative resection: a multicentre analysis. <i>Minerva Surgery</i> , 2021, , .	0.1	1
39	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 688889.	1.3	7
40	Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe. <i>Breast</i> , 2021, 59, 232-238.	0.9	5
41	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , 2021, 60, 6-14.	0.9	8
42	Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2817.	0.8	5
43	Masaoka-Koga and TNM Staging System in Thymic Epithelial Tumors: Prognostic Comparison and the Role of the Number of Involved Structures. <i>Cancers</i> , 2021, 13, 5254.	1.7	7
44	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
45	Postoperative vacuum therapy following AMS <sup>®</sup> , LGX 700 <sup>®</sup> inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. <i>International Journal of Impotence Research</i> , 2020, 32, 133-139.	1.0	6
46	Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2020, 6, 463-478.	1.6	72
47	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
48	Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 832-839.	0.3	22
49	Dermoscopy and confocal microscopy for different chemotherapy-induced alopecia (CIA) phases characterization: Preliminary study. <i>Skin Research and Technology</i> , 2020, 26, 269-276.	0.8	3
50	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11
51	Comparison between single-site and multiport robot-assisted hysterectomy in obese patients with endometrial cancer: An Italian multi-institutional study. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2020, 16, e2066.	1.2	7
52	Interplay between male testosterone levels and the risk for subsequent invasive respiratory assistance among COVID-19 patients at hospital admission. <i>Endocrine</i> , 2020, 70, 206-210.	1.1	43
53	External validation of the N descriptor in the proposed tumour "node" metastasis subclassification for lung cancer: the crucial role of histological type, number of resected nodes and adjuvant therapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1236-1244.	0.6	11
54	Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 315-323.	0.5	8

#	ARTICLE	IF	CITATIONS
55	Does Follow-Up Duration Affect the Effectiveness of a Predictive Nomogram Model for Thymic Malignancy Recurrences? Results From an External Validation. <i>Journal of Thoracic Oncology</i> , 2020, 15, e137-e139.	0.5	2
56	BRAF status modulates Interleukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. <i>Communications Biology</i> , 2020, 3, 546.	2.0	8
57	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
58	How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?. <i>Frontiers in Surgery</i> , 2020, 7, 563006.	0.6	17
59	A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9432.	1.8	2
60	Biofilm Production by Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Significantly Increases the Risk of Death in Oncological Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 561741.	1.8	30
61	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
62	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5325-5334.	0.7	20
63	Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. <i>BMC Cancer</i> , 2020, 20, 418.	1.1	6
64	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 111.	3.5	14
65	Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 464-471.e1.	1.1	8
66	Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study. <i>Diagnostic Cytopathology</i> , 2020, 48, 1034-1040.	0.5	14
67	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
68	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	0.9	4
69	Pattern of recurrence in patients with endometrial cancer: A retrospective study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1697-1702.	0.5	15
70	Clinical management of very small pigmented lesions: Improved clinical outcome through dermoscopy and reflectance confocal microscopy combination. <i>Skin Research and Technology</i> , 2020, 26, 718-726.	0.8	2
71	Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 68.	3.5	16
72	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. <i>Cancers</i> , 2020, 12, 849.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. <i>ESMO Open</i> , 2020, 5, e000689.	2.0	11
74	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16769-e16769.	0.8	1
75	Prevention of fistulas after salvage laryngectomy using temporoparietal fascia free flap. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, 181-189.	0.7	7
76	The actin modulator <i>hMENA</i> regulates <i>GAS</i> $\beta$ - <i>AXL</i> axis and promotes tumor cancer/stromal cell cooperation. <i>EMBO Reports</i> , 2020, 21, e50078.	2.0	20
77	A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility. <i>Asian Journal of Andrology</i> , 2020, 22, 360.	0.8	52
78	Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12056-12056.	0.8	0
79	HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer. <i>Oncology Reports</i> , 2020, 45, 899-910.	1.2	2
80	Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. <i>Recenti Progressi in Medicina</i> , 2020, 111, 761-768.	0.8	0
81	First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. <i>Clinical Breast Cancer</i> , 2019, 19, e701-e716.	1.1	10
82	Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis. <i>Anticancer Research</i> , 2019, 39, 4917-4924.	0.5	6
83	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. <i>Nucleic Acids Research</i> , 2019, 47, 3365-3382.	6.5	34
84	Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical Series. <i>World Neurosurgery</i> , 2019, 127, e751-e760.	0.7	7
85	The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker. <i>Surgical Oncology</i> , 2019, 28, 151-157.	0.8	13
86	Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. <i>Oncologist</i> , 2019, 24, 612-616.	1.9	43
87	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	1.0	8
88	Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 405-412.	0.6	38
89	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	1.5	30
90	Italian validation of the functional difficulties questionnaire (FDQ) and its correlation with major determinants of quality of life in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 25-34.	1.1	11

#	ARTICLE	IF	CITATIONS
91	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
92	The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience. <i>Updates in Surgery</i> , 2019, 71, 67-75.	0.9	20
93	The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. <i>Alcohol and Alcoholism</i> , 2019, 54, 47-50.	0.9	4
94	Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis. <i>Minerva Medica</i> , 2019, 110, 330-340.	0.3	25
95	The clinical Biofilm Ring Test: a promising tool for the clinical assessment of biofilm-producing <i>Candida</i> species. <i>FEMS Yeast Research</i> , 2018, 18, .	1.1	9
96	Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronieâ€™s Disease. <i>Journal of Urology</i> , 2018, 200, 642-647.	0.2	29
97	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	1.5	12
98	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 568-575.	0.5	17
99	Chromogranin A as a biomarker for prostate cancer: is it actually relevant for clinical practice?. <i>Future Oncology</i> , 2018, 14, 1233-1235.	1.1	5
100	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 527-535.	1.4	16
101	Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 772-779.	1.3	28
102	Neoadjuvant chemotherapy in tripleâ€negative breast cancer: A multicentric retrospective observational study in realâ€life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	2.0	33
103	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 191-198.	1.1	5
104	Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. <i>Clinical Colorectal Cancer</i> , 2018, 17, e13-e19.	1.0	26
105	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
106	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
107	Renal cancer: new models and approach for personalizing therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 217.	3.5	17
108	How is stereotactic brain biopsy evolving? A multicentric analysis of a series of 421 cases treated in Rome over the last sixteen years. <i>Clinical Neurology and Neurosurgery</i> , 2018, 174, 101-107.	0.6	17

#	ARTICLE	IF	CITATIONS
109	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolimmunology</i> , 2018, 7, e1465163.	2.1	6
110	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	0.9	31
111	Inflammatory cytokines and biofilm production sustain <i>Staphylococcus aureus</i> outgrowth and persistence: a pivotal interplay in the pathogenesis of Atopic Dermatitis. <i>Scientific Reports</i> , 2018, 8, 9573.	1.6	56
112	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	1.8	16
113	Exploring relationships between joint hypermobility and neurodevelopment in children (4–13 years) with hereditary connective tissue disorders and developmental coordination disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 546-556.	1.1	19
114	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	3.5	27
115	Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 139.	3.5	38
116	Comparison of Different Surgical Approaches for Stage IB1 Cervical Cancer Patients: A Multi-institution Study and a Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1020-1028.	1.2	80
117	hMENA isoforms impact NSCLC patient outcome through fibronectin/ $\beta$ 1 integrin axis. <i>Oncogene</i> , 2018, 37, 5605-5617.	2.6	17
118	Kyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 cases. <i>Clinical Neurology and Neurosurgery</i> , 2018, 171, 184-189.	0.6	6
119	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model. <i>Journal of Clinical Oncology</i> , 2018, 36, 542-542.	0.8	1
120	Induction Therapy versus Initial Surgery in Advanced Thymic Tumors: Perioperative and Oncological Outcome. <i>Thoracic and Cardiovascular Surgeon</i> , 2017, 65, 234-243.	0.4	7
121	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e661-e666.	0.9	47
122	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. <i>Scientific Reports</i> , 2017, 7, 43013.	1.6	44
123	Refining patterns of joint hypermobility, <i>habitus</i> , and orthopedic traits in joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 914-929.	0.7	20
124	Meeting report: Vitiligo Global Issues Consensus Conference Workshop – Outcome measurement instruments and Vitiligo International Symposium, Rome, Nov 30–Dec 3rd. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 436-443.	1.5	14
125	IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. <i>Cancer Research</i> , 2017, 77, 3268-3279.	0.4	49
126	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017, 13, 1517-1525.	1.1	4



#	ARTICLE	IF	CITATIONS
127	Prognostic impact of proliferation for resected early stage "pure" invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017, 35, 21-26.	0.9	16
128	Lentigo maligna of the face: A quantitative simple method to identify individual patient risk probability on dermoscopy. <i>Australasian Journal of Dermatology</i> , 2017, 58, 286-291.	0.4	3
129	The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1971-1976.	1.2	41
130	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. <i>Cancer Medicine</i> , 2017, 6, 1233-1239.	1.3	9
131	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	128
132	Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis. <i>Lung</i> , 2017, 195, 107-114.	1.4	5
133	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	2.0	16
134	SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage. <i>Nucleic Acids Research</i> , 2017, 45, 1820-1834.	6.5	43
135	Biofilm is a Major Virulence Determinant in Bacterial Colonization of Chronic Skin Ulcers Independently from the Multidrug Resistant Phenotype. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1077.	1.8	77
136	Prevalence and determinants of oral infection by Human Papillomavirus in HIV-infected and uninfected men who have sex with men. <i>PLoS ONE</i> , 2017, 12, e0184623.	1.1	26
137	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017, 8, 54528-54536.	0.8	10
138	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5030-5030.	0.8	5
139	Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12504-e12504.	0.8	3
140	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. <i>Oncotarget</i> , 2017, 8, 108463-108479.	0.8	8
141	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. <i>Oncotarget</i> , 2017, 8, 69025-69037.	0.8	12
142	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	0.8	53
143	Survival of cancer patients in Italy. <i>Epidemiologia E Prevenzione</i> , 2017, 41, 1-244.	1.1	22
144	Establishment of patient-derived renal cell carcinoma (RCC) models based on orthotopic xenografts (PDX) and cancer stem cell (CSC) isolation to provide prognostic and predictive information.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16055-e16055.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16521-e16521.	0.8	0
146	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 539-539.	0.8	0
147	Serum and Urine Free Light Chain Cut-off Detection for a Rational Employment of the Bence-Jones Proteinuria Test in Presence of Monoclonal Gammopathy. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2017, 27, 143-149.	0.1	0
148	Observational prospective study to evaluate survival, quality of life and cost of oncologic treatments for advanced non small cell lung cancer (NSCLC) patients that progressed after a first line of treatment: preliminary analysis. <i>Annals of Oncology</i> , 2016, 27, iv13.	0.6	0
149	Development of an in vitro Assay, Based on the BioFilm Ring Test <sup>®</sup> , for Rapid Profiling of Biofilm-Growing Bacteria. <i>Frontiers in Microbiology</i> , 2016, 7, 1429.	1.5	47
150	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , 2016, 17, 105.	1.4	10
151	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016, 11, e0157751.	1.1	17
152	Robotic single site versus robotic multiport hysterectomy in early endometrial cancer: a case control study. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e39.	1.0	18
153	Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC): cut-off analysis and clinical validation. <i>Annals of Oncology</i> , 2016, 27, iv62.	0.6	0
154	Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model. <i>Annals of Oncology</i> , 2016, 27, iv7.	0.6	0
155	A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results. <i>Annals of Oncology</i> , 2016, 27, iv33.	0.6	0
156	Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial. <i>Annals of Oncology</i> , 2016, 27, iv66.	0.6	0
157	Narrative Medicine: a multidisciplinary study on knowledge and application in oncology. <i>Annals of Oncology</i> , 2016, 27, iv110.	0.6	0
158	Surgical and Oncological Outcome of Robotic Surgery Compared With Laparoscopic and Abdominal Surgery in the Management of Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 539-546.	1.2	27
159	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , 2016, 29, 24-30.	0.9	9
160	The pattern of hMENA isoforms is regulated by TGF- $\beta$ 21 in pancreatic cancer and may predict patient outcome. <i>Oncolmmunology</i> , 2016, 5, e1221556.	2.1	23
161	Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 193.	3.5	7
162	Polyfunctional Melan-A-specific tumor-reactive CD8 <sup>+</sup> T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. <i>Oncolmmunology</i> , 2016, 5, e1114203.	2.1	25

#	ARTICLE	IF	CITATIONS
163	Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment. Archives of Dermatological Research, 2016, 308, 309-318.	1.1	18
164	Trends in the use of partial nephrectomy for cT1 renal tumors: Analysis of a 10-yr European multicenter dataset. European Journal of Surgical Oncology, 2016, 42, 1729-1735.	0.5	35
165	Appropriateness of knee MRI prescriptions: clinical, economic and technical issues. Radiologia Medica, 2016, 121, 315-322.	4.7	25
166	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage "pure" and "mixed" lobular breast cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 50.	3.5	4
167	ALPPS for primary and secondary liver tumors. International Journal of Surgery, 2016, 30, 38-44.	1.1	35
168	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. Breast, 2016, 29, 96-101.	0.9	16
169	Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC). Scientific Reports, 2016, 6, 34006.	1.6	16
170	Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. Scientific Reports, 2016, 6, 22982.	1.6	16
171	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. Breast, 2016, 30, 151-155.	0.9	32
172	Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients. The Ful500 prospective observational trial. Annals of Oncology, 2016, 27, vi82.	0.6	0
173	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. Journal of Cellular Physiology, 2016, 231, 986-991.	2.0	12
174	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	1.4	25
175	MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head and Neck, 2016, 38, E189-97.	0.9	45
176	Spine Surgery in Patients with Metastatic Breast Cancer: A Retrospective Analysis. World Neurosurgery, 2016, 90, 133-146.	0.7	6
177	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist, 2016, 21, 283-291.	1.9	45
178	Serial <sup>18</sup> F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncology, 2016, 12, 333-342.	1.1	31
179	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. Critical Reviews in Oncology/Hematology, 2016, 98, 254-263.	2.0	2
180	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	2.9	56

#	ARTICLE	IF	CITATIONS
181	Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 47-57.e1.	0.4	39
182	Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
183	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016, 7, 43188-43198.	0.8	35
184	Italian cancer figures--Report 2015: The burden of rare cancers in Italy. <i>Epidemiologia E Prevenzione</i> , 2016, 40, 1-120.	1.1	44
185	Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A real life retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 337-337.	0.8	2
186	Abstract A003: Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. , 2016, , .		0
187	Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS). <i>Journal of Clinical Oncology</i> , 2016, 34, 545-545.	0.8	0
188	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC). <i>Journal of Clinical Oncology</i> , 2016, 34, 544-544.	0.8	0
189	Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients. , 2016, , .		0
190	Abstract A040: The low antitumor functionality of PD1-positive gp100-specific CD8+ T cell clones isolated from melanoma patients correlates with the presence of CD28 co-stimulatory molecule. , 2016, , .		0
191	Abstract A113: The pattern of hMENA isoforms is regulated by TGF- $\beta$ 1 in pancreatic cancer and may predict patient outcome. , 2016, , .		0
192	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	1.6	55
193	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 156.	3.5	54
194	Noninvasive assessment of benign pigmented genital lesions using reflectance confocal microscopy. <i>British Journal of Dermatology</i> , 2015, 173, 1312-1315.	1.4	6
195	Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF monoclonal antibody: an observational multicenter study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2363-2368.	1.3	20
196	Age-related prevalence and morphological appearance of facial skin tumours: a prospective, cross-sectional, observational, multicentre study with special emphasis on melanocytic tumours. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1331-1338.	1.3	4
197	Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment?. <i>Tumori</i> , 2015, 101, 469-473.	0.6	36
198	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015, 10, e0127908.	1.1	21

#	ARTICLE	IF	CITATIONS
199	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
200	Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 262-270.	3.4	14
201	Surgical and oncological outcome of robotic surgery compared to laparoscopic and abdominal surgery in the management of endometrial cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1074-1081.	0.5	52
202	The efficacy of a photolyase-based device on the cancerization field: a clinical and thermographic study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 84.	3.5	17
203	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1341-1348.	0.5	18
204	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 53.	6.9	32
205	Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II- $\beta$ Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel. <i>Clinical Breast Cancer</i> , 2015, 15, 16-23.	1.1	6
206	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	3.4	83
207	Mini-laparoscopic versus robotic radical hysterectomy plus systematic pelvic lymphadenectomy in early cervical cancer patients. A multi-institutional study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 136-141.	0.5	30
208	PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 15.	3.5	68
209	Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis. <i>Annals of Thoracic Surgery</i> , 2015, 100, 890-897.	0.7	19
210	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 319-324.	0.9	5
211	Detection of Phosphorylated Insulin Receptor in Colorectal Adenoma and Adenocarcinoma: Implications for Prognosis and Clinical Outcome. <i>Journal of Cellular Physiology</i> , 2015, 230, 562-567.	2.0	18
212	A laboratory test based on determination of cytokine profiles: a promising assay to identify exposition to contact allergens and predict the clinical outcome in occupational allergic contact dermatitis. <i>BMC Immunology</i> , 2015, 16, 4.	0.9	10
213	Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi's sarcoma and non-Kaposi's cases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 1.	3.5	62
214	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	3.5	15
215	Spectrum of mucocutaneous manifestations in 277 patients with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2015, 169, 43-53.	0.7	30
216	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	0.9	43

#	ARTICLE	IF	CITATIONS
217	Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis. <i>Neuroscience Letters</i> , 2015, 606, 156-160.	1.0	22
218	Quality of life and functional evaluation in patients with tongue base tumors treated exclusively with transoral robotic surgery: A 1-year follow-up study. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2015, 43, 1561-1566.	0.7	26
219	Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis. <i>Clinical and Experimental Dermatology</i> , 2015, 40, 136-141.	0.6	16
220	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59.	2.0	14
221	Sun Protection Among Spanish Beachgoers: Knowledge, Attitude and Behaviour. <i>Journal of Cancer Education</i> , 2015, 30, 4-11.	0.6	30
222	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 12783-12795.	0.8	58
223	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. <i>World Journal of Gastroenterology</i> , 2015, 21, 4788.	1.4	56
224	FOLFIRINOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. <i>Journal of Clinical Oncology</i> , 2015, 33, 372-372.	0.8	0
225	Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16054-e16054.	0.8	0
226	Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A retrospective multicenter observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11542-e11542.	0.8	0
227	Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 549-549.	0.8	0
228	Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14585-e14585.	0.8	0
229	Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study. <i>Journal of Cancer</i> , 2014, 5, 320-327.	1.2	53
230	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. <i>Tumori</i> , 2014, 100, e309-e313.	0.6	0
231	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Cancer</i> , 2014, 5, 398-405.	1.2	8
232	Overall Prognosis of Advanced Breast Cancer (Abc) According to Chemotherapy (Ct) Treatment Lines: Correlation Analysis Between Progression-Free-, Post-Progression- and Overall- Survival (Pfs, Pps and Overall Survival) in a Retrospective Study. <i>Journal of Cancer</i> , 2014, 5, 320-327.	0.6	0
233	Fact- B and Esas in Metastatic Breast Cancer (Mbc) Patients (Pts) Treated with Eribulin: Results of a Multicenter Prospective Observational Study. <i>Annals of Oncology</i> , 2014, 25, iv472.	0.6	0
234	Her2-Positive Early Breast Cancer in the Pre-Trastuzumab and Trastuzumab Eras: a Triple Positive Subgroup Analysis of a Multicenter Retrospective Study. <i>Annals of Oncology</i> , 2014, 25, iv99.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Treatment (T) of Metastatic Colorectal Cancer (Mrc) Patients (Pts) ≥75 Years (Y) Old in Clinical Practice: a Multicenter Analysis. <i>Annals of Oncology</i> , 2014, 25, iv205.	0.6	0
236	Molecular Portrait of Resected Gastric Cancer (Rgc) with Next Generation Sequencing (Ngs) According to a Clinical Biological Risk Model Considering Fhit, Apc and Her-2 Overexpression. <i>Annals of Oncology</i> , 2014, 25, iv219.	0.6	0
237	Clinical Impact of Folfirinox Dose/Schedule Modifications (Mfolforinox) and Additional Supportive Measures in the Management of Pancreatic Cancer (Pdac) Patients (Pts). <i>Annals of Oncology</i> , 2014, 25, iv234.	0.6	1
238	Treatment and Outcome(S) of a Large Cohort of Poor Risk Metastatic Renal Cell Carcinoma (Prrcc) Patients (Pts). <i>Annals of Oncology</i> , 2014, 25, iv290.	0.6	0
239	Risk Stratification Model for Resected Squamous Cell Lung Cancer (R-Sqlc) Patients (Pts) According to Clinical and Pathological Factors. <i>Annals of Oncology</i> , 2014, 25, iv412.	0.6	0
240	Next Generation Sequencing (Ngs) Reveals Qualitative and Quantitative Molecular Heterogeneity Within Egfr-Mutant Advanced Lung Adenocarcinoma (Ala) Patients (Pts) Receiving Gefitinib (G). <i>Annals of Oncology</i> , 2014, 25, iv462.	0.6	0
241	Therapeutic Targeting of Raf-Induced Paradoxical Erk Activation with a Vertical Combination Hitting Multiple Steps Along the Mapk Cascade. <i>Annals of Oncology</i> , 2014, 25, iv549.	0.6	0
242	BMI variation increases recurrence risk in women with early-stage breast cancer. <i>Future Oncology</i> , 2014, 10, 2459-2468.	1.1	23
243	HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 96.	3.5	22
244	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	1.1	39
245	Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 63.	3.5	4
246	Reflectance Confocal Microscopy Features of Seborrheic Dermatitis for Plaque Psoriasis Differentiation. <i>Dermatology</i> , 2014, 229, 215-221.	0.9	31
247	Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: The role of US, MRI and FDG-PET/TC scans to assess residual neck disease. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, 1834-1839.	0.7	22
248	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 847-856.	3.4	20
249	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 135-145.	2.0	12
250	Optimal tolerability and high efficacy of a modified schedule of lapatinib+capecitabine in advanced breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 221-226.	1.2	8
251	Early-onset colorectal cancer patients without family history are at very low risk for lynch syndrome. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 1.	3.5	63
252	CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. <i>Cell Stem Cell</i> , 2014, 14, 342-356.	5.2	617

#	ARTICLE	IF	CITATIONS
253	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24
254	Nosology and inheritance pattern(s) of joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type: A study of intrafamilial and interfamilial variability in 23 Italian pedigrees. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 3010-3020.	0.7	70
255	High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory thrombotic processes. <i>Neurological Sciences</i> , 2014, 35, 1737-1741.	0.9	16
256	MicroRNA expression profiling of thymic epithelial tumors. <i>Lung Cancer</i> , 2014, 85, 197-204.	0.9	43
257	Breast Cancer "Tailored Follow-up" in Italian Oncology Units: A Web-Based Survey. <i>PLoS ONE</i> , 2014, 9, e94063.	1.1	8
258	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. <i>Oncotarget</i> , 2014, 5, 11054-11063.	0.8	32
259	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15568-e15568.	0.8	0
260	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥75 years (y) old in clinical practice: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14514-e14514.	0.8	0
261	Prognostic value of <i>ALK</i> gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19059-e19059.	0.8	0
262	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
263	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	0.6	1
264	Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity after radioembolization with yttrium-90 resin microspheres. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 13.	3.5	16
265	Improving Sun-Safe Knowledge, Attitude and Behaviour in Parents of Primary School Children: a Pilot Study. <i>Journal of Cancer Education</i> , 2013, 28, 151-157.	0.6	26
266	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	1.2	8
267	Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 853-860.	1.2	38
268	Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study. <i>Supportive Care in Cancer</i> , 2013, 21, 1691-1695.	1.0	14
269	Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?. <i>SpringerPlus</i> , 2013, 2, 185.	1.2	1
270	Cutaneous melanoma follow-up: appropriateness of requests for ultrasound tests " the S.Gallicano National Referral Centre Experience. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 73.	3.5	7



#	ARTICLE	IF	CITATIONS
271	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	6.9	42
272	Typical and atypical dermoscopic presentations of dermatofibroma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1375-1380.	1.3	43
273	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 89.	3.5	8
274	Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. <i>Annals of Oncology</i> , 2013, 24, 3082-3088.	0.6	89
275	Increased incidence of thyroid cancer in Latina, Italy: A possible role of detection of subclinical disease. <i>Cancer Epidemiology</i> , 2013, 37, 262-269.	0.8	23
276	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 699-706.	0.9	16
277	Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. <i>Journal of Neuro-Oncology</i> , 2013, 113, 313-325.	1.4	74
278	Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. <i>Investigational New Drugs</i> , 2013, 31, 1035-1043.	1.2	12
279	Both mucosal and cutaneous papillomaviruses are in the oral cavity but only alpha genus seems to be associated with cancer. <i>Journal of Clinical Virology</i> , 2013, 56, 72-76.	1.6	29
280	A clinical "biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. <i>Annals of Oncology</i> , 2013, 24, 693-701.	0.6	55
281	Evaluation of Relapse-Free Survival in T3N0 Colon Cancer: The Role of Chemotherapy, a Multicentric Retrospective Analysis. <i>PLoS ONE</i> , 2013, 8, e80188.	1.1	10
282	Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy. <i>Dermatology Research and Practice</i> , 2013, 2013, 1-7.	0.3	7
283	Assessment of T Regulatory Cells and Expanded Profiling of Autoantibodies May Offer Novel Biomarkers for the Clinical Management of Systemic Sclerosis and Undifferentiated Connective Tissue Disease. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-7.	3.3	12
284	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 4511.	1.4	13
285	Histopathological Assessment in Glossectomy. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 1076-1082.	1.1	6
286	An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0. <i>Acta Haematologica</i> , 2012, 127, 149-151.	0.7	4
287	EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 672-680.	0.5	28
288	Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. <i>Head and Neck</i> , 2012, 34, 328-335.	0.9	17

#	ARTICLE	IF	CITATIONS
289	Analysis of the miR-34a locus in 62 patients with familial cutaneous melanoma negative for CDKN2A/CDK4 screening. <i>Familial Cancer</i> , 2012, 11, 201-208.	0.9	10
290	Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: a pilot study. <i>Supportive Care in Cancer</i> , 2012, 20, 1221-1226.	1.0	19
291	The importance of physician-patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability. <i>Neurological Sciences</i> , 2012, 33, 575-584.	0.9	37
292	Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). <i>Leukemia Research</i> , 2012, 36, 443-447.	0.4	23
293	Excised melanocytic lesions in children and adolescents - a 10-year survey. <i>British Journal of Dermatology</i> , 2012, 167, 368-373.	1.4	45
294	Supraorbital keyhole approach for removal of midline anterior cranial fossa meningiomas: a series of 20 consecutive cases. <i>Neurosurgical Review</i> , 2012, 35, 67-83.	1.2	43
295	Progression-free survival (PFS) with maintenance treatment with bevacizumab (B) in patients with responding mCRC after first-line chemotherapy (CT) plus B.. <i>Journal of Clinical Oncology</i> , 2012, 30, 612-612.	0.8	0
296	Evaluation of relapse-free survival in T3N0 colon cancer: The role of chemotherapy-A multicentric retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 578-578.	0.8	1
297	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. <i>Clinical Cancer Research</i> , 2011, 17, 2055-2064.	3.2	92
298	Circulating Autoantibodies to Phosphorylated $\alpha$ -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112.	1.8	119
299	Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. <i>Cancer Epidemiology</i> , 2011, 35, e116-e120.	0.8	24
300	Seven-point checklist of dermoscopy revisited. <i>British Journal of Dermatology</i> , 2011, 164, 785-790.	1.4	130
301	Dose and polymorphic genes <i>xrcc1</i> , <i>xrcc3</i> , <i>gst</i> play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. <i>BMC Cancer</i> , 2011, 11, 291.	1.1	14
302	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. <i>Journal of Translational Medicine</i> , 2011, 9, 184.	1.8	55
303	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 10.	3.5	89
304	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 54.	3.5	29
305	Colorectal cancer after breast cancer: A case-control study. <i>Cancer Epidemiology</i> , 2011, 35, 44-47.	0.8	4
306	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 768-769.	13.9	140

#	ARTICLE	IF	CITATIONS
307	Dermoscopy of Pigmented Lesions of the Vulva: A Retrospective Morphological Study. <i>Dermatology</i> , 2011, 222, 157-166.	0.9	51
308	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 2277-2285.	0.6	86
309	P1-07-07: Assessing Two Methods of Meta-Analysis in Studies of Patients with Breast Cancer: Individual Patient Data-Based (IPD) Versus Literature Based Abstracted Data (AD) in 5 Meta-Analyses Including over 28,000 Patients. Are There Results Differences of Concern?. , 2011, , .		0
310	Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome,) Tj ETQq0 0 0 rgBT /Overlock 10	0.48	57
311	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , 2010, 100, 209-215.	1.4	17
312	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010, 85, 314-320.	1.1	23
313	Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. <i>British Journal of Cancer</i> , 2010, 103, 324-331.	2.9	218
314	Cetuximab plus chromomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. <i>British Journal of Cancer</i> , 2010, 103, 1542-1547.	2.9	157
315	Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies. <i>Oncology</i> , 2010, 78, 141-149.	0.9	29
316	Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer. <i>Oncologist</i> , 2010, 15, e1-e4.	1.9	7
317	Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. <i>Journal of Translational Medicine</i> , 2010, 8, 36.	1.8	16
318	Epithelial to Mesenchymal Transition Is Impaired in Colon Cancer Cells With Microsatellite Instability. <i>Gastroenterology</i> , 2010, 138, 1406-1417.	0.6	106
319	Skin cancer risk factors among primary school children: Investigations in Western Hungary. <i>Preventive Medicine</i> , 2010, 51, 320-324.	1.6	24
320	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. <i>BMC Cancer</i> , 2010, 10, 675.	1.1	18
321	Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 166.	3.5	9
322	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 58.	3.5	46
323	Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers. <i>Oncology</i> , 2009, 76, 254-261.	0.9	41
324	Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. <i>Annals of Oncology</i> , 2009, 20, 1728-1735.	0.6	144

#	ARTICLE	IF	CITATIONS
325	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , 2009, 9, 101.	1.1	28
326	Serum level of CD26 predicts time to first treatment in early Bâ€chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009, 83, 208-214.	1.1	8
327	Arterial Access-Siteâ€Related Outcomes of Patients Undergoing Invasive Coronary Procedures for Acute Coronary Syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Tj ETQq1 1 0.784314 rgBT /Overlaid <i>American Journal of Cardiology</i> , 2009, 103, 796-800.	0.7	113
328	Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?. <i>Cancer</i> , 2009, 115, 3446-3456.	2.0	82
329	Adenocarcinoma of the Esophagogastric Junction: The Role of Abdominal-Transhiatal Resection. <i>Annals of Surgical Oncology</i> , 2009, 16, 304-310.	0.7	32
330	Genetic profile identification in clinically localized prostate carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 502-508.	0.8	11
331	Transradial access compared with femoral puncture closure devices in percutaneous coronary procedures. <i>International Journal of Cardiology</i> , 2009, 137, 199-205.	0.8	62
332	Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. <i>Lung Cancer</i> , 2009, 63, 50-57.	0.9	44
333	A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. <i>Lung Cancer</i> , 2009, 66, 365-371.	0.9	81
334	Pharmacokinetics of Gemcitabine at Fixed-Dose Rate Infusion in Patients with Normal and Impaired Hepatic Function. <i>Clinical Pharmacokinetics</i> , 2009, 48, 131-141.	1.6	12
335	Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 157.	3.5	30
336	Sexual dysfunction following surgery for rectal cancer - a clinical and neurophysiological study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 128.	3.5	27
337	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 35.	3.5	8
338	Deficient DNA Mismatch Repair Is Common in Lynch Syndrome-Associated Colorectal Adenomas. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 238-247.	1.2	97
339	Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. <i>Anti-Cancer Drugs</i> , 2009, 20, 109-114.	0.7	3
340	Abstract B115: The epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. , 2009, , .		0
341	Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 231-239.	1.1	137
342	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 717-725.	1.1	39

#	ARTICLE	IF	CITATIONS
343	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2008, 88, 374-380.	0.7	12
344	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , 2008, 16, 1375-1380.	1.0	11
345	Taxanes as primary chemotherapy for early breast cancer. <i>Cancer</i> , 2008, 113, 238-246.	2.0	56
346	A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008, 60, 381-386.	0.9	6
347	A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities. <i>Clinical Colorectal Cancer</i> , 2008, 7, 273-279.	1.0	8
348	High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: Long term survival data. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 115.	2.2	0
349	A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. <i>Breast Cancer Research</i> , 2008, 10, R74.	2.2	89
350	P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: Distribution and prognostic relevance. <i>European Journal of Cancer</i> , 2008, 44, 1217-1222.	1.3	25
351	Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 593-598.	0.5	22
352	Clinical Role of p16INK4a Expression in Liquid-Based Cervical Cytology. <i>American Journal of Clinical Pathology</i> , 2008, 129, 606-612.	0.4	23
353	Induction of ErbB-3 Expression by $\alpha_5\beta_1$ Integrin Contributes to Tamoxifen Resistance in ER <sup>-</sup> Negative Breast Carcinomas. <i>PLoS ONE</i> , 2008, 3, e1592.	1.1	47
354	Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4158-4158.	0.6	9
355	Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER <sup>2</sup> Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 1467-1469.	1.9	34
356	HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant. <i>American Journal of Surgical Pathology</i> , 2007, 31, 76-84.	2.1	22
357	Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin + paclitaxel in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2007, 18, 227-232.	0.7	14
358	Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile. <i>American Journal of Surgical Pathology</i> , 2007, 31, 247-254.	2.1	5
359	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs</i> , 2007, 18, 687-692.	0.7	6
360	Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. <i>Radiotherapy and Oncology</i> , 2007, 84, 148-155.	0.3	58

#	ARTICLE	IF	CITATIONS
361	4013 POSTER Hypofractionation versus standard fraction in prostate cancer: analysis of the acute toxicity. <i>European Journal of Cancer, Supplement, 2007, 5, 283.</i>	2.2	0
362	5526 POSTER Xerostomia and related quality of life in patients treated with intensity modulated radiation therapy for nasopharyngeal cancer: initial report of a prospective study. <i>European Journal of Cancer, Supplement, 2007, 5, 332.</i>	2.2	0
363	6576 POSTER Extent of mediastinal lymph-nodes resection as prognostic factor for survival in stage Iâ€“IIIa non-small-cell lung cancer (NSCLC) patients undergone surgery: a retrospective analysis of a mono-institutional series. <i>European Journal of Cancer, Supplement, 2007, 5, 381.</i>	2.2	0
364	Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?. <i>Clinical Breast Cancer, 2007, 7, 550-554.</i>	1.1	38
365	Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases. <i>Cancer, 2007, 109, 274-281.</i>	2.0	73
366	Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. <i>British Journal of Cancer, 2007, 97, 593-597.</i>	2.9	13
367	Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. <i>British Journal of Cancer, 2007, 97, 1040-1045.</i>	2.9	20
368	Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer. <i>Experimental and Molecular Pathology, 2007, 83, 385-391.</i>	0.9	7
369	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. <i>Journal of Clinical Investigation, 2007, 117, 3236-3247.</i>	3.9	212
370	Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. <i>Cancer Letters, 2006, 237, 76-82.</i>	3.2	17
371	Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. <i>European Journal of Cancer, 2006, 42, 608-616.</i>	1.3	22
372	Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. <i>European Journal of Cancer, 2006, 42, 1501-1506.</i>	1.3	37
373	Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs, 2006, 17, 345-351.</i>	0.7	4
374	Immunohistochemical expression of p16INK4a is predictive of HR-HPV infection in cervical low-grade lesions. <i>Modern Pathology, 2006, 19, 384-391.</i>	2.9	124
375	Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluorouracil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study. <i>Cancer Chemotherapy and Pharmacology, 2006, 57, 59-64.</i>	1.1	13
376	Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. <i>Cancer Chemotherapy and Pharmacology, 2006, 57, 615-623.</i>	1.1	20
377	A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. <i>Annals of Oncology, 2006, 17, 630-636.</i>	0.6	73
378	Chromogenic In Situ Hybridization to Detect HER2/neu Gene Amplification in Histological and ThinPrep Â®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era. <i>Oncologist, 2006, 11, 878-886.</i>	1.9	47

#	ARTICLE	IF	CITATIONS
379	Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. <i>Journal of Surgical Oncology</i> , 2005, 90, 95-100.	0.8	64
380	Impact of gefitinib (Iressa™) treatment on the quality of life of patients with advanced non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 783-788.	1.2	10
381	Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. <i>Journal of Clinical Pathology</i> , 2005, 58, 367-371.	1.0	29
382	P-538 Sequential treatment with docetaxel-cisplatin (DP) doublet allows higher conversion to response for patients (pts) with advanced NSCLC in stable disease (SD) after 2 courses of gemcitabine-cisplatin (GP): Preliminary results of a pilot study. <i>Lung Cancer</i> , 2005, 49, S259.	0.9	0
383	Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 52-59.	1.0	11
384	Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. <i>European Journal of Cancer</i> , 2004, 40, 1624-1629.	1.3	20
385	Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1065-1071.	0.6	53
386	Role of P53 and Bcl-2 in Advanced Rectal Carcinomas Treated with Adjuvant Therapy. <i>Journal of Chemotherapy</i> , 2004, 16, 11-14.	0.7	0
387	A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. <i>British Journal of Cancer</i> , 2003, 89, 1870-1875.	2.9	19